Cue Biopharma, Inc. (CUE)

Cue Biopharma, Inc. (CUE) Healthcare & Pipeline Overview

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company specializing in Immuno-STAT biologics for cancer, chronic infectious diseases, and autoimmune disorders. Their lead candidate, CUE-101, is in Phase 1b trials targeting HPV-driven cancers, positioning them in the competitive immunotherapy landscape.

What Is the Investment Thesis for CUE?

Cue Biopharma's investment thesis centers on its innovative Immuno-STAT platform, which aims to selectively modulate the immune system. The Phase 1b clinical trial of CUE-101 for HPV-driven cancers represents a key value driver. Successful trial outcomes and potential FDA approval could significantly increase the company's market capitalization. Collaboration agreements with Merck and LG Chem provide validation and potential revenue streams. However, the company's negative profit margin of -96.9% and reliance on clinical trial success pose significant risks. Upcoming clinical trial data releases will be critical catalysts. The company's relatively small market cap of $86.72M suggests high growth potential but also increased volatility.

Based on FMP financials and quantitative analysis

CUE Key Highlights

• Market Cap of $86.72M reflects its status as a clinical-stage biopharmaceutical company with significant growth potential.
• Gross Margin of 88.0% indicates strong potential profitability upon successful commercialization of its drug candidates.
• Profit Margin of -96.9% highlights the current reliance on R&D investments and the absence of revenue-generating products.
• Beta of 1.58 suggests higher volatility compared to the overall market, typical for biotechnology stocks.
• Lead drug candidate CUE-101 is in Phase 1b clinical trial, a critical milestone for potential future revenue.

Who Are CUE's Competitors?

CUE is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CUE's Key Strengths?

• Innovative Immuno-STAT technology platform.
• Lead drug candidate in Phase 1b clinical trials.
• Collaboration agreements with Merck and LG Chem.
• Strong gross margin potential.

What Are CUE's Weaknesses?

• Negative profit margin.
• Reliance on clinical trial success.
• Small market capitalization.
• Limited number of employees.

What Could Drive CUE Stock Higher?

• Release of Phase 1b clinical trial data for CUE-101 in HPV-driven cancers.
• Progress of CUE-102 and CUE-103 through preclinical and clinical development.
• Potential for new collaboration agreements with pharmaceutical companies.
• Advancements in the development of CUE-200 for chronic infections.

What Are the Key Risks for CUE?

• Financial-distress signal — its Altman Z-Score of -12.35 sits in the distress zone (elevated bankruptcy risk).
• Negative return on equity (-98.3%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for CUE-101 or other drug candidates.
• Regulatory delays or rejection of drug approvals.
• Competition from larger pharmaceutical companies with more resources.
• Challenges in securing funding for ongoing research and development.
• Intellectual property disputes or challenges to patent protection.

What Are the Growth Opportunities for CUE?

• Expansion of CUE-101 into additional HPV-driven cancers: The success of CUE-101 in its current Phase 1b trial could pave the way for expanding its application to other HPV-related malignancies. The global market for HPV-related cancer treatments is projected to reach billions of dollars, providing a substantial growth opportunity for Cue Biopharma if CUE-101 demonstrates efficacy and safety across a broader range of HPV-driven cancers. Timeline for expansion depends on clinical trial results and regulatory approvals.
• Advancement of CUE-102 and CUE-103 programs: Progressing CUE-102 and CUE-103 through clinical trials represents a significant growth opportunity. These Immuno-STATs target different cancer pathways, expanding Cue Biopharma's potential market reach. Positive clinical data could attract further investment and partnership opportunities. The timeline for these programs depends on preclinical and clinical trial outcomes, with potential market entry within the next 3-5 years.
• Development of CUE-200 for chronic infections: CUE-200, designed to address T cell exhaustion in chronic infections, represents a novel approach to treating diseases like HIV and hepatitis. The market for chronic infection therapies is substantial, and successful development of CUE-200 could provide a significant revenue stream. The timeline for CUE-200's development depends on preclinical and clinical trial results, with potential for clinical trials to begin within the next 2 years.
• Partnerships and collaborations: Cue Biopharma's existing collaborations with Merck and LG Chem provide a foundation for future partnerships. Expanding these collaborations or establishing new ones could accelerate drug development and provide additional funding. Strategic partnerships can also provide access to new technologies and markets. The timeline for new partnerships is variable and depends on business development efforts and market opportunities.
• Expansion into autoimmune diseases: The CUE-300 and CUE-400 frameworks targeting autoimmune diseases represent a long-term growth opportunity. The autoimmune disease market is large and growing, with significant unmet needs. Successful development of therapies in this area could significantly increase Cue Biopharma's market value. The timeline for these programs is longer-term, with potential for clinical trials to begin in the next 3-5 years.

What Opportunities Does CUE Have?

• Expansion of CUE-101 into additional HPV-driven cancers.
• Advancement of CUE-102 and CUE-103 programs.
• Development of CUE-200 for chronic infections.
• Expansion into autoimmune diseases.

What Threats Does CUE Face?

• Clinical trial failures.
• Regulatory hurdles.
• Competition from larger pharmaceutical companies.
• Funding challenges.

What Are CUE's Competitive Advantages?

• Proprietary Immuno-STAT technology platform.
• Patent protection for drug candidates.
• Collaboration agreements with major pharmaceutical companies.
• Clinical trial data demonstrating efficacy and safety.

What Does CUE Do?

Cue Biopharma, Inc., founded in 2014 and headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing a novel class of biologics called Immuno-STATs. These biologics are designed to selectively modulate the human immune system to treat various cancers, chronic infectious diseases, and autoimmune disorders. The company's lead drug candidate, CUE-101, is a fusion protein biologic currently in Phase 1b clinical trials, targeting antigen-specific T cells for human papillomavirus (HPV)-driven cancers. Cue Biopharma's pipeline includes CUE-102, a fusion protein biologic targeting antigen-specific T cells to fight cancers, and CUE-103, an Immuno-STAT targeting the KRAS G12V mutation prevalent in colorectal carcinoma, lung cancer, and pancreatic cancer. They are also developing CUE-200, which focuses on cell surface receptors like CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections, and the CUE-300 and CUE-400 frameworks targeting various autoimmune diseases. The company has established collaboration agreements with Merck Sharp & Dohme Corp. for autoimmune disease research, LG Chem Life Sciences for oncology-focused Immuno-STAT development, and Albert Einstein College of Medicine. Formerly known as Imagen Biopharma, Inc., the company rebranded as Cue Biopharma, Inc. in October 2016 to reflect its refined focus on immune modulation.

What Products and Services Does CUE Offer?

• Develop biologic drugs for immunomodulation.
• Target cancers, chronic infectious diseases, and autoimmune disorders.
• Utilize Immuno-STAT technology to selectively activate T cells.
• Advance CUE-101, a fusion protein biologic, through clinical trials for HPV-driven cancers.
• Develop CUE-102 and CUE-103 for various cancer types.
• Create CUE-200 to address T cell exhaustion in chronic infections.
• Establish collaboration agreements with pharmaceutical companies and research institutions.

How Does CUE Make Money?

• Develop and patent novel Immuno-STAT biologics.
• Conduct preclinical and clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from agencies like the FDA.
• Out-license or commercialize approved drugs.

What Industry Does CUE Operate In?

Cue Biopharma operates within the competitive biotechnology industry, characterized by high R&D spending and lengthy regulatory approval processes. The immunotherapy market, which Cue Biopharma targets, is experiencing substantial growth, driven by advancements in cancer treatment and autoimmune disease therapies. Key trends include personalized medicine and targeted therapies. Competition includes major pharmaceutical companies and smaller biotech firms developing similar immunomodulatory drugs. Cue Biopharma's Immuno-STAT platform aims to differentiate itself through selective immune system modulation.

Who Are CUE's Key Customers?

• Pharmaceutical companies through collaboration agreements.
• Patients with cancers, chronic infectious diseases, and autoimmune disorders (upon drug approval).
• Healthcare providers who prescribe and administer the drugs (upon drug approval).

FY2026 estForward Outlook

Wall Street analysts project Cue Biopharma, Inc. revenue of about $12.8M for fiscal 2026, with EPS near $-6.64.

Quarterly Financial Performance: Cue Biopharma, Inc.

Revenue for Cue Biopharma, Inc. came in at $5.7M during Q1 2026, a 74.1% contraction versus the preceding quarter. The company recorded a net loss of $5.2M, with diluted EPS of $-1.08. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, CUE averaged $-1.38 in diluted EPS.

CUE Valuation & Market Position

With a $86.72M market cap, Cue Biopharma, Inc. sits in the micro-cap segment of the market. Relative to its peer group, CUE's quantitative score of 20/100 is below the peer average of 85/100.

ROE -98%Key Financial Metrics

Return on equity for Cue Biopharma, Inc. stands at -98.3%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -63.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -29.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 3.57 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -12.9%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 2/9Financial Health

Cue Biopharma, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -12.35 places it in the distress zone, a signal of elevated financial risk.

Company Profile

Cue Biopharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Boston, US. The company is led by CEO Lucinda Warren. CUE has traded publicly since 2018.

CUE Financials

CUE Latest News

CUE Analyst Consensus

CUE MoonshotScore

Latest Cue Biopharma, Inc. Analysis

Cue Biopharma, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources